Drug Trial Radar · NCT07089589
Preoperative Statin Use and Major Adverse Cardiovascular Events in Liver Transplant Recipients
Last checked: Nov 19, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,898
Actual
Start
Jan 2, 2008
Primary completion
Jan 25, 2026
Study completion Mar 22, 2026
Sponsor
- Lead sponsor
- Asan Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Samsung Medical Center; Inje University Haeundae Paik Hospital
- First posted
- Jul 28, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this multicenter observational study is to determine whether preoperative statin use reduces major adverse cardiovascular events or other complications after liver transplantation. The main question it aims to answer is: Does preoperative statin use reduce major adverse cardiovascular events or other complications after liver transplantation? The records of participants who already took statins before liver transplantation will be reviewed.
Conditions
- Major Adverse Cardiovascular Events
- Liver Transplantation
Interventions
Preoperative Statin UseDrug
Administration of any statin medication prior to liver transplantation. Statin therapy was previously prescribed by the treating physician before the transplant procedure, not assigned by the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 30-day Major Adverse Cardiovascular EventsTime frame: 30 days after liver transplantation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.